American Brain Tumor Association 2017 report cites that cancer is the second largest cause for death globally responsible for the death of approximately 8.8 million patients. World Health Organization predicts the growth of cancer incidence to reach 70% in next 20 years. Gamma knife devices faces stringent market competition by other types of radiosurgery such as Linear Accelerator Systems (LINAC) and Cyclotron. They have meritorious features in comparison to gamma knife in treating larger tumor in larger areas of brain and other body parts and precisely target only the tumor cells, causing least harm to the surrounding healthy cells.
Gamma knife devices are employed for cancer treatment by indications such as benign tumors, malignant tumors, functional disorders, vascular disorders and ocular diseases. The performance of gamma knife devices as a therapy for the indication segment is elucidated as market estimation and data forecast.
The five major regional segment comprising of their major countries are covered under the geography segment:
Geographical segment for gamma knife devices consists of country cross sectional market estimation and data forecast for 2015-2025.
Technological evolution in the gamma knife devices such as the radiation doses utilized, composite isocenters and automated shielding for enhanced device safety and accuracy are studied in the company profiles section. Latest merger and acquisition within the premier players are mentioned under recent news coverage. The competitive landscape gives information about the existing monopoly in gamma knife devices e.g. Elekta AB and ambitious business tactics applied by other major players to capture the market. The foremost leaders in the development of gamma knife devices for cancer treatment are Elekta AB, American Shared Hospital Services, Hokai, Cyber Medical Corporation Limited, ET Medical Group, Huiheng Medical, Inc., Masep Infini Global, Inc., Nordion, Inc. and Varian Medical Systems, Inc.